Note: Descriptions are shown in the official language in which they were submitted.
METHOD FOR SHAPING TISSUE MATRICES
[0001]
[0002] The present disclosure relates to tissue matrices, and more
particularly, to methods for shaping tissue matrices and tissue products
produced
according to those methods.
[0003] Various tissue-derived products are used to regenerate,
repair,
or otherwise treat diseased or damaged tissues and organs. Such products can
include intact tissue grafts and/or acellular or reconstituted acellular
tissues (e.g.,
acellular tissue matrices from skin, intestine, or other tissues, with or
without cell
seeding). However, such tissues generally have a shape defined by their tissue
of
origin. For example, dermal or intestinal products will generally include
sheets of
relatively flexible materials.
[0004] To treat certain tissue or organ defects, it may be
desirable to
form predefined shapes or configurations that more closely conform to anatomic
structures to be treated. Accordingly, methods for altering the shape of
tissue
matrices, as well as tissue matrices produced using those methods, are
provided.
SUMMARY
[0005] According to certain embodiments, a method for shaping a
tissue
matrix is provided. The method comprises selecting a collagen-containing
tissue
matrix; partially dehydrating the tissue matrix; applying mechanical forces to
the
tissue matrix to change the orientation of at least some of the collagen
fibers
within the tissue matrix; and exposing the tissue matrix to radiation.
[0006] In certain embodiments, a tissue product is provided. The
product comprises an extracellular tissue matrix comprising collagen, wherein
the
CA 2804592 2018-04-05
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
extracellular tissue matrix has a stable three-dimensional shape formed by a
process comprising partially dehydrating the extracellular tissue matrix;
applying
mechanical forces to the tissue matrix to reorient at least some of the
collagen
fibers within the tissue matrix; and exposing the tissue matrix to radiation.
[0007] In certain embodiments, a tissue product is provided. The
product comprises an extracellular tissue matrix comprising collagen fibers,
wherein at least some of the collagen fibers within the matrix have an
orientation
that is different than the orientation of the fibers in a tissue from which
the matrix
is produced and the matrix forms a stable three dimensional shape, and wherein
the matrix has a denaturation temperature as measured with differential
scanning
calorimetry that is within 5 C of the denaturation temperature of the tissue
from
which the matrix is produced.
[0008] In certain embodiments, a tissue product is provided. The
product comprises an extracellular tissue matrix comprising collagen fibers,
wherein at least some of the collagen fibers within the matrix have an
orientation
that is different than the orientation of the fibers in a tissue from which
the matrix
is produced, and wherein the matrix forms a stable three-dimensional shape
without using chemical cross-linking agents. The stable shape can be formed by
partially dehydrating the tissue product and exposing the product to
radiation.
DESCRIPTION OF THE DRAWINGS
[0009] Fig. 1 is a shaped tissue product, according to certain
embodiments.
[0010] Fig. 2 is a shaped tissue product, according to certain
embodiments.
2
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
[0011] Fig. 3 is a shaped tissue product, according to certain
embodiments.
[0012] Fig. 4 is a differential scanning calorimetry thermogram for an
acellular human dermal material and a shaped tissue product produced according
to certain embodiments.
[0013] Figs. 5A-5D are scanning electron micrographs for an acellular
human dermal material and a shaped tissue product produced according to
certain embodiments.
[0014] Fig. 6 is a differential scanning calorimetry thermogram for an
acellular porcine dermal material and a shaped tissue product produced
according
to certain embodiments.
[0015] Figs. 7A-7D are scanning electron micrographs for an acellular
porcine dermal material and a shaped tissue product produced according to
certain embodiments.
[0016] Fig. 8 is a plot of the diffusion rate of fluorescein
isothiocyanate
(FITC)-labeled borine serum albumin (BSA) across tissue matrix sheets in a
Franz-cell diffusion chamber for an acellular porcine dermal material and a
shaped tissue product produced according to certain embodiments.
[0017] Fig. 9 includes fluorescence microscopy images of an acellular
porcine dermal material and a shaped tissue product after exposure to
fluorescein
isothiocyanate (FITC)-labeled BSA in a Franz-cell diffusion chamber.
[0018] Fig. 10 is a photo of an acellular porcine dermal material and
shaped tissue product produced according to certain embodiments.
3
[0019] Figs. 11A-11 D are scanning electron micrographs for an
acellular
porcine artery and a shaped tissue product produced according to certain
embodiments.
[0020] Fig. 12A is a scanning electron micrograph of a shaped
tissue
product produced according to certain embodiments.
[0021] Fig. 12B is a scanning electron micrograph of a shaped
tissue
product produced according to certain embodiments.
DESCRIPTION OF CERTAIN EXEMPLARY EMBODIMENTS
[0022] Reference will now be made in detail to certain exemplary
embodiments according to the present disclosure, certain examples of which are
illustrated in the accompanying drawings. Wherever possible, the same
reference
numbers will be used throughout the drawings to refer to the same or like
parts.
[0023] In this application, the use of the singular includes the
plural
unless specifically stated otherwise. In this application, the use of "or"
means
"and/or" unless stated otherwise. Furthermore, the use of the term
"including", as
well as other forms, such as "includes" and "included", is not limiting. Any
range
described herein will be understood to include the endpoints and all values
between the endpoints.
[0024] The section headings used herein are for organizational
purposes only and are not to be construed as limiting the subject matter
described.
4
CA 2804592 2018-04-05
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
[0025] As used herein "tissue product" and "shaped tissue product" will
refer to any human or animal tissue that contains an extracellular matrix and
that
has been processed to change the orientation of at least some of the collagen
fibers within the extracellular matrix. "Tissue products" can include
acellular or
partially decellularized tissue matrices, decellularized tissue matrices that
have
been repopulated with exogenous cells, and/or cellular tissues that have been
processed to change the orientation of at least some of the collagen fibers
within
the tissue's extracellular matrix.
[0026] Various human and animal tissues can be used to produce
products for treating patients. For example, various tissue products for
regeneration, repair, augmentation, reinforcement, and/or treatment of human
tissues that have been damaged or lost due to various diseases and/or
structural
damage (e.g., from trauma, surgery, atrophy, and/or long-term wear and
degeneration) have been produced. Such products can include, for example,
acellular tissue matrices, tissue allografts or xenografts, and/or
reconstituted
tissues (i.e., at least partially decellularized tissues that have been seeded
with
cells to produce viable materials).
[0027] In certain embodiments, these products can be completely or
partially decellularized to yield acellular tissue matrices or extracellular
tissue
materials to be used for patients. For example, various tissues, such as skin,
intestine, bone, cartilage, nerve tissue (e.g., nerve fibers or dura),
tendons,
ligaments, or other tissues can be completely or partially decellularized to
produce
tissue products useful for patients. In some cases, these decellularized
products
can be used without addition of exogenous cellular materials (e.g., stem
cells). In
certain cases, these decellularized products can be seeded with cells from
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
autologous sources or other sources, such as xenogenic or allogenic sources,
to
facilitate treatment. Suitable processes for producing acellular tissue
matrices are
described below.
[0028] Tissue products can be selected to provide a variety of different
biological and mechanical properties. For example, an acellular tissue matrix
or
other tissue product can be selected to allow tissue ingrowth and remodeling
to
assist in regeneration of tissue normally found at the site where the matrix
is
implanted. For example, an acellular tissue matrix, when implanted on or into
fascia, may be selected to allow regeneration of the fascia without excessive
fibrosis or scar formation. In certain embodiments, the tissue product can be
formed from ALLODERMO or STRATTICETm, which are human and porcine
acellular dermal matrices respectively. Alternatively, other suitable
acellular tissue
matrices can be used, as described further below. The methods for shaping
tissues having an extracellular matrix can be used to process any collagenous
tissue type, and for any tissue matrix product. For example, a number of
biological scaffold materials are described by Badylak et al., and the methods
of
the present disclosure can be used to produce tissues with a stable three-
dimensional shape using any of those materials, or any other similar
materials.
Badylak et al., "Extracellular Matrix as a Biological Scaffold Material:
Structure and
Function," Acta Biomaterialia (2008), doi:10.1016/j.actbio.2008.09.013.
[0029] Most tissues, when first harvested from an animal or cadaver
donor, retain the general shape of the original tissue source. For example, a
skin
graft, when first dissected from a donor, will generally form a flat, flexible
sheet
when placed on a flat surface. Similarly, urinary bladder, small intestine,
blood
vessels, dura, and other materials will retain the shape of the original
tissue
6
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
source. Further, when cut and processed (e.g., to produce an acellular tissue
matrix) most tissues can be laid on a flat surface to form a relatively flat
sheet.
[0030] For some applications, it may be desirable to alter the shape of
tissue products. For example, acellular tissue matrices are implanted at a
variety
of different anatomic sites, and it may be beneficial to control the shape of
the
tissue matrices to more closely conform to the desired shape when implanted.
For example, acellular tissue matrices or other tissue products can be
implanted
around breast implants; around or replacing vascular structures; around or
replacing lumina! structures (e.g., ureters, nerves, lymphatic tissues,
gastrointestinal structures); on or replacing heart valves, pericardium, or
other
cardiac structures; in or on bony or cartilaginous materials (e.g., ears,
noses,
articular surfaces, around dental structures, or along any short of long
bone);
and/or surrounding, lining, supporting, or replacing any body cavity (e.g.,
bladder,
stomach). However, some processes that may alter the shape of a tissue product
to form a stable three-dimensional structure can also alter the tissue matrix
in
undesirable ways. For example, chemical cross-linking can be used to form a
stable three-dimensional structure, but excessive cross-linking can alter the
biologic properties of the tissue, and chemical cross-linking agents may be
harmful to patients when implanted in a patient. Accordingly, methods for
controlling the shape of tissue products are provided.
[0031] According to certain embodiments, a method for shaping a tissue
matrix is provided. The method comprises selecting a collagen-containing
tissue
matrix; partially dehydrating the tissue matrix; applying mechanical forces to
the
tissue matrix to change the orientation of collagen fibers within the tissue
matrix;
and exposing the tissue matrix to radiation. In certain embodiments, a tissue
7
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
product is provided. The product comprises an extracellular tissue matrix
comprising collagen, wherein the extracellular tissue matrix has a three-
dimensional shape formed by a process comprising partially dehydrating the
extracellular tissue matrix; applying mechanical forces to the tissue matrix
to
reorient collagen fibers within the tissue matrix; and exposing the tissue
matrix to
radiation. In certain embodiments, a tissue product is provided, which
comprises
an extracellular tissue matrix comprising collagen fibers, wherein the
extracellular
tissue matrix forms a stable three-dimensional shape that is different than a
three-
dimensional shape of a tissue from which the matrix is produced, and wherein
the
matrix has a denaturation temperature, as measured with differential scanning
calorimetry, is within 5 C of the denaturation temperature of the tissue from
which
the matrix is produced. In certain embodiments, a tissue product is provided.
The
product comprises an extracellular tissue matrix comprising collagen fibers,
wherein at least some of the collagen fibers within the matrix have an
orientation
that is different than the orientation of the fibers in a tissue from which
the matrix
is produced, and wherein the matrix forms a stable three-dimensional shape
without using chemical cross-linking agents.
[0032] As noted above, the tissue products of the present disclosure
comprise an extracellular matrix that has a stable three-dimensional shape.
The
three-dimensional shape can be selected to conform to any anatomic structure
and/or to perform any desired structural or functional task in or on a
patient's
body. For example, Figs. 1-3 are shaped tissue products, according to certain
embodiments. Fig. 1 is a cup-shaped device 10, having a convex back surface 12
and a concave inner surface 14. Cup-shaped tissue products may be useful to
support breast implants, e.g., for breast augmentation and/or reconstruction.
For
8
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
example, the inner surface 14 may be placed around a breast implant and
attached to surrounding fascia, muscle, or other tissue to help secure a
breast
implant in a proper position, to reduce or prevent scar formation, or to
otherwise
alter the aesthetic appearance of an implant. In addition, such devices by be
used
to reinforce body cavities (e.g., bladder or stomach).
[0033] Such devices can be modified, e.g., made oblong, completely
spherical, and/or more convex or concave, as the need may be. Further, the
shape can be made as a custom-shaped product, e.g., to conform to specific
anatomic or aesthetic requirements, or can be a standard size for a particular
application (e.g., to conform to standard implants, such as a breast implant,
used
in conjunction with the shaped tissue products). Tissue products may be made
by
joining the edges of tissue to form a seam, for example by sutures, adhesive,
or
other connection mechanisms. In addition, tissue products may be folder or
otherwise bent to a desired shape.
[0034] Fig. 2 is a tubular device 20 having a lumen 24. If formed from a
sheet of tissue, the device 20 may include a seam 26 that is held together
with
sutures, adhesive, or other connection mechanisms. Tubular devices may be
useful for treatment of conditions related to bodily luminal structures and/or
for
treatment of connective tissue structures. For example, a tubular structure
may
be useful for treating, replacing, or reinforcing vascular structures (e.g.,
arteries or
veins), as a conduit to assist in nerve repair or regeneration, and/or to
replace,
repair, or regenerated tendons, ligaments, or fascia. The methods of the
present
disclosure can be used to produce three-dimensional shapes for any anatomic
structure. Fig. 3 is a drawing of a nose-shaped tissue product 28 that was
produced from an acellular dermal matrix using methods of the present
disclosure.
9
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
Tissue products having such a shape have been produced. Products having
shapes conforming to any desired anatomic structure can be produced using the
methods described herein.
[0035] The collagen-containing tissue matrix can include an acellular
tissue matrix or a tissue matrix that forms part of an intact or partially
decellularized tissue. In some embodiments, the tissue matrix comprises a
dermal tissue matrix. In certain embodiments, the tissue is selected from
fascia,
pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac
valve
tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural
connective tissue, urinary bladder tissue, ureter tissue, and intestinal
tissue.
[0036] As noted, the process of shaping tissue products includes
partially dehydrating tissues. It has been discovered that partial dehydration
of
tissues causes the extracellular matrix of collagenous materials to become
more
pliable, thereby allowing collagen fibers to be reoriented. However, excessive
dehydration, e.g., by freeze-drying, can make tissues brittle, and therefore,
excessive dehydration can damage tissues during subsequent processing steps.
[0037] A variety of suitable processes can be used to partially
dehydrate
the tissue matrix. For example, suitable methods can include blot-drying with
water-absorbent towels, isothermal water desorption with controlled humidity,
applying mechanical forces to tissues, centrifugation, and/or controlled
and/or
directional freezing. Any suitable method can be used to partially dehydrate
the
matrix as long as the method does not cause undesirable tissue alterations
such
as changes in collagen or other protein structure, loss of growth factors,
and/or
excessive cross-linking.
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
[0038] In various embodiments, the amount of dehydration is selected
based on the tissue type to be processed and the desired shapes to be
produced.
In some embodiments, the tissue is dehydrated to produce a tissue matrix
containing between 95%(w/w) and 50%(w/w) water content. In other
embodiments, the tissue product is dehydrated to produce a water content that
is
between 80%(w/w) and 65%(w/w), 50-90%, 50-85%, 50-80%, 50-90%, 60-90%,
65-90%, or any values therebetween.
[0039] After partial dehydration, mechanical forces are applied to
tissues or acellular tissue matrices to reorient collagen fibers within the
extracellular matrix of the tissues. This can be done in a variety of ways, as
long
as forces are directed in such a way to produce a final desired shape. In some
embodiments, a mold having a desired shape is produced, and a sheet of tissue
or acellular tissue matrix, which has been partially dehydrated, is placed in
contact
with the mold. Forces are then applied to portions of the sheet to reorient
fibers to
produce a tissue product having a shape corresponding to the mold. For
example, in some embodiments, to produce a cup-shaped product, as shown in
Fig. 1, a mold having a convex surface is used, and a sheet is stretched or
pulled
over the mold and held in place with sutures. Similarly, to produce a tubular
product, as shown in Fig. 2, a dowel rod or other tubular structure is
selected as a
mold, and a sheet of tissue or acellular tissue matrix is wrapped around the
sheet.
[0040] The amount, direction, and/or manner of applying force may
depend in the shape that is desired. For example, for a relatively simple
shape, it
may be sufficient to simply lay a sheet of acellular tissue over a mold having
the
desired shape, and additional force may be applied to stretch of compress the
matrix. In other cases, for example, to produce a more complex shape, a sheet
of
11
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
acellular tissue matrix can be placed on a mold, and a second mold having a
corresponding configuration can be placed on top of the acellular tissue
matrix to
compress the matrix and form a desired shape.
[0041] For example, as described above, Fig. 3 illustrates another
shaped tissue product 28, according to certain embodiments. Product 28 has a
nose shape, and may be used as a tissue graft to repair or reshape nasal
structures. Product 28 was produced by placing an acellular dermal matrix
between two shaped molds, to produce the desired shape, and irradiating the
matrix in the shaped configuration.
[0042] After collagen fibers are reoriented, tissue products are treated to
stabilize the three-dimensional structures of the extracellular matrix. The
structure
is can be stabilized by exposing the tissue product to radiation. Radiation
may
cause a small degree of tissue cross-linking sufficient to produce a stable
three-
dimensional structure. The stable structure will tend to conform to a shape
similar
to the mold (or shape of the matrix at the time of irradiation), but will
generally be
sufficiently flexible to allow the tissue product to be manipulated during
surgery
and to function as a soft-tissue graft. For example, a tissue product shaped
as a
cup for a breast implant, will be flexible enough to conform to a breast
implant and
not produce undersirable texture, while maintaining a relatively cup-shaped
configuration in a resting state. Similarly, a tubular product for a vascular
device
will be sufficiently flexible to allow bending, anastomosis with a vascular
site, and
expansion under vascular pressure, but will maintain a tubular shape when in a
resting state (i.e., when no external mechanical forces are placed on it).
[0043] In various embodiments, the amount of radiation to which the
product is exposed can be between 5 Gy and 50 kGy, or between 5 Gy and 20
12
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
kGy. In certain embodiments, the radiation is applied at a dose of less than
10
kGy, less than 5 kGy, or less than 1 kGy. Suitable forms of radiation can
include
gamma radiation, e-beam radiation, and X-ray radiation.
[0044] As noted above, the tissue products of the present disclosure
can form a stable three-dimensional structure without causing undesirable
alterations in the tissue matrix. For example, although cross-linking may
assist in
maintaining a three-dimensional shape, excessive crosslinking can alter the
biological properties of tissue products. Therefore, in some embodiments, the
tissue product will maintain a three-dimensional structure without excessive
cross-
linking.
[0045] Tissue cross-linking can be measured by an increase in a
denaturation temperatures of a tissue matrix, as measured with differential
scanning calorimetry. Accordingly, in some embodiments, tissue products of the
present disclosure include an extracellular tissue matrix that forms a stable
three-
dimensional shape that is different than a three-dimensional shape of a tissue
from which the matrix is produced, and wherein the matrix has a denaturation
temperature on a differential scanning calorimetry thermogram that is within 5
C
of the denaturation temperature of the tissue from which the matrix is
produced.
In certain embodiments, the denaturation temperature as measured with
differential scanning calorimetry is within 3 C, within 2 C, or within 1 C of
the
denaturation temperature of the tissue from which the matrix is produced. In
various embodiments, the denaturation temperature can be at a peak on the DSC
curve, or be identified as an average from the denaturation onset to end
temperature, so long as the same method is used to identify the denaturation
temperature in the source and processed tissues. Further, since chemical
13
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
crosslinking agents can cause non-uniform and excessive crosslinking and/or
may
be harmful, the method of the present disclosure allows formation of a matrix
that
has a stable three-dimensional shape without using chemical cross-linking
agents
by partial dehydration and irradiation.
[0046] As noted above, "shaped tissue products," can include acellular
or partially decellularized tissue matrices, decellularized tissue matrices
that have
been repopulated with exogenous cells, and/or cellular tissues that have been
processed to change the orientation of at least some of the collagen fibers
within
the tissue's extracellular matrix. Accordingly, in various embodiments, tissue
products may be processed (e.g., to remove cellular components to produce
acellular tissue matrices, and/or to remove antigenic materials), using steps
other
than those needed to shape the tissue product. In various embodiments, the
methods for shaping tissue products can be performed before and/or after other
processing steps. For example, for an acellular tissue matrix product, the
shaping
can be performed after the decellularization process or on the intact tissue,
which
is then processed to remove cells. Further, in some embodiments, since
radiation
is used to stabilize the three-dimensional shape, the irradiation step may be
performed as part of a terminal sterilization step to both stabilize the
tissue
product shape and destroy pathogens. In other embodiments, radiation is
applied
to the tissue product to produce a stable three-dimensional shape, and the
tissue
is sterilized using subsequent radiation steps and/or other sterilization
processes.
[0047] In
addition, tissue products shaped according to the methods of
the present disclosure may be packaged and/or rehydrated. In certain
embodiments, the products can be stabilized with low-dose radiation then
14
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
rehydrated and packaged. Subsequent to packaging, the products may be
terminally sterilized with additional radiation or using other sterilization
processes.
[0048] In certain embodiments, tissue products produced according to
methods of the present disclosure have a permeability that is different than
the
permeability of tissue matrices from which they are made. In various
embodiments, the permeability can be to liquids, including aqueous liquids,
such
as blood, serosanguinous fluids, urine, or other bodily fluids.
[0049] In certain embodiments, the shaped tissue products will have a
reduced permeability to liquids than the matrices from which they are
produced.
Tissue products having a reduced permeability may be more suitable for
treating
anatomic sites exposed to large amounts of fluids, or which should retain or
exclude fluids to perform normal functions. For example, when repairing,
replacing, or regenerating portions of vascular or urinary structures, it may
be
desirable to have a reduced (or little to no) permeability, thereby preventing
leakage of floods such as blood or urine while cellular ingrowth and tissue
regeneration occurs. Therefore, in certain embodiments, shaped tissue products
can include tubular structures that are substantially impermeable to blood or
pouch like structures that are impermeable to blood, urine, or other fluids.
[0050] It will be understood that the benefits and advantages described
above may relate to one embodiment or may relate to several embodiments. It
will further be understood that reference to 'an' item refers to one or more
of those
items.
[0051] Where appropriate, aspects of any of the examples and
embodiments described above may be combined with aspects of any of the other
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
examples described to form further examples having comparable or different
properties and addressing the same or different problems.
[0052] It will be understood that the above description of preferred
embodiments is given by way of example only and that various modifications may
be made by those skilled in the art. The above specification, examples and
data
provide a complete description of the structure and use of exemplary
embodiments of the invention. Although various embodiments of the invention
have been described above with a certain degree of particularity, or with
reference
to one or more individual embodiments, those skilled in the art could make
numerous alterations to the disclosed embodiments without departing from the
scope of this invention.
Experiment #1 - Reorientation of Collagen Fibers in Acellular Human
Dermis
Processing of Tissue to Decellularize and Reorient Collagen Fibers:
[0053] Human skin from cadaver donors was obtained, and the upper
portion was split to a thickness of about 2 mm. The donor skin was de-
epidermized for 17 hours at room temperature by incubation in a 1.0 M sodium
chloride solution containing 0.5% (w/v) TRITON X100. The tissue was de-
cellularized by incubation for 22 hours in 2% (w/v) sodium deoxycholate. The
de-
epidermized and de-cellularized tissue matrix was washed in Dulbecco's
phosphate-buffered saline (PBS, pH 7.5) containing 5 mM
ethylenediaminetetraacetic acid (EDTA), and was frozen at -80 C for temporary
storage. Frozen dermis was thawed at room temperature (-22 C) and rinsed with
Dulbecco's PBS solution overnight.
16
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
[0054] The tissue matrix was partially dehydrated by blot-drying with
sterile GAMMA WIPES to achieve tissue matrix hydration of 3.12 0.22 g water
per gram dry mass (mean standard deviation, N = 3) or a final water content
of
75.7% (w/w). The partial dehydration represented the removal of ¨51% of the
water in the tissue matrix. The blotting process was also used to apply
mechanical pressure (compression) to the partially dehydrated tissue matrix to
cause reorientation of collagen fibers within the tissue matrix.
[0055] Dehydrated and reoriented tissue matrix samples were sealed in
sterile plastic film bags. The plastic film bags were then sealed in secondary
foil-
to-foil bags and were irradiated with 500 Gy gamma radiation over 35 minutes.
After radiation, the tissue matrix was rehydrated in PBS. The water content of
the
rehydrated tissue matrices were 4.92 0.31 gram water per gram of dry tissue
mass (N = 3) or 83.1% (w/w), representing a 57.7% increase during rehydration
in
PBS. The rehydrated human tissue matrices had an estimated porosity of about
88 1% (N = 3).
Differential Scanning Calorimetry:
[0056] Differential scanning calorimetry (DSC) was used to assess the
differences between control tissue matrices (decellularized but not subjected
to
collagen reorientation) and rehydrated shaped tissue product. Fig. 4 is a
differential scanning calorimetry thermogram for a control acellular human
dermal
material and a shaped tissue product. As shown, the thermograms for the
control
material and the shaped tissue product were very similar, having a similar
denaturation temperature indicating little collagen crosslinking or damage.
Therefore, the collagen fiber reorientation with partial dehydration and low
dose
17
CA 02804592 2013-01-07
WO 2012/006390
PCT/1JS2011/043129
gamma radiation did not significantly alter the structure and stability of the
collagen fibers and the tissue matrix.
Electron Microscopy:
[0057] Rehydrated tissue matrices were fixed in 2% glutaraldehyde for
24 hours and dehydrated sequentially in 25%, 50%, 75%, 90%, 98% and 100%
(v/v) ethanol solutions. The duration of each ethanol dehydration step was at
least 2 hours. Ethanol-dehydrated samples were dried in hexamethyldisilazane
and were then sputter-coated with gold before scanning electron microscope
(SEM) observation under 10 kilovolts.
[0058] Figs. 5A-5D are scanning electron micrographs for control
acellular human dermal material (Figs. 5A and 5B) and a shaped tissue product
(Figs. 5C and 5D). The low magnification images (Figs. 5A and 5C) show that
the
treatment resulted in collagen fiber realignment. Further, the higher
magnification
images (Figs. 5B and 5D) demonstrate that the processing did not alter the
collagen fiber structures.
Experiment #2¨ Reorientation of Collagen Fibers in Acellular Porcine
Dermis
Processing of Tissue to Decellularize and Reorient Collagen Fibers:
[0059] Porcine skin was split to remove the epidermis and
subcutaneous fat. The remaining tissue was 1.9 0.2 mm thick (N = 5). The
tissue was de-cellularized by incubation in 2% (w/v) sodium deoxycholate for
24
hours at room temperature, and was then washed three times with PBS for 2
hours each wash. The de-cellularized dermal matrix was partially dehydrated by
blot-drying with sterile GAMMA WIPES to achieve a tissue hydration level of
2.34 0.37 gram water per gram of dry tissue mass or a final water content of
18
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
70% (w/w). The dehydration removed ¨43% tissue water. The blotting process
was also used to applied mechanical pressure (compression) to the tissue
matrix
to cause reorientation of collagen fibers within the tissue matrix.
[0060] Tissue samples were sealed in sterile plastic film bags. The
plastic bags were sealed in secondary foil-to-foil bags and were irradiated
with
500 Gy gamma-irradiation over 35 min. After gamma irradiation, porcine dermal
matrix was rehydrated in PBS. The fully rehydrated tissue matrix had a
hydration
of 2.84 0.38 gram water per gram dry tissue mass (N = 10) or a water content
of
74% (w/w). The rehydrated porcine dermis matrix had an estimated porosity
about 80 2% (N = 10) according to the water content in tissue matrix.
Differential Scanning Calorimetry:
[0061] Differential scanning calorimetry (DSC) was used to assess
differences between control tissue matrices (decellularized but not subjected
to
collagen reorientation) and the rehydrated shaped tissue product. Fig. 6 is a
differential scanning calorimetry thermogram for a control acellular porcine
dermal
material and a shaped tissue product. As shown, the thermograms for the
control
material and the shaped tissue product were similar, as the shaped tissue
product
had a denaturation temperature on the thermogram that was shifted to a
slightly to
higher temperature (1 to 2 C). The small shift caused by collagen
reorientation
and gamma irradiation was indicative of a small amount of collagen
crosslinking.
Electron Microscopy:
[0062] Rehydrated samples were fixed, dehydrated, and prepared in the
manner described in Example 1 for SEM observation. Figs. 7A-7D are scanning
electron micrographs for a control acellular porcine dermal material (Figs. 7A
and
7B) and a shaped tissue product (Figs. 70 and 7D). The low magnification
19
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
images (Figs. 7A and 7C) show that the treatment resulted in collagen fiber
realignment. Further, the higher magnification images (Figs. 7B and 7D)
demonstrate that the processing brought collagen fibers closer to each others,
but
did not alter the collagen fiber structures.
Tissue Permeability:
[0063] A Franz-cell diffusion chamber with a 0.9 cm opening was used
to measure the diffusion rate of fluorescein isothiocyanate (FITC)-labeled BSA
across tissue matrix sheets. The concentration of FITC-BSA was maintained at
pg/ml at the donor chamber. The fluorescence of the solution in the receptor
chamber was measured every hour for 7 hours. On completion of the diffusion
assay, tissue samples were cryo-sectioned to 10-micron slices and imaged using
a fluorescence-microscope.
[0064] Fig. 8 is a plot of the diffusion rate of fluorescein
isothiocyanate
(FITC)-labeled BSA across tissue matrix sheets in a Franz-cell diffusion
chamber
for an acellular porcine dermal material and a shaped tissue product produced
as
described in this example. Fig. 9 includes fluorescence microscopy images of
an
acellular porcine dermal material and a shaped tissue product, respectively,
after
exposure to Fluorescein isothiocyanate (FITC)-labeled BSA in a Franz-cell
diffusion chamber.
[0065] As shown, in the diffusion rate plot and microscopy images, the
diffusion rate through the shaped tissue product was significantly less than
the
diffusion rate through the acellular porcine dermal matrix that had not been
reshaped. This data demonstrates that the collagen realignment method can
modify the permeability of a tissue matrix, and can reduce the permeability of
tissue matrices.
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
Experiment #3- Shaping of Flat Acellular Porcine Dermal Sheets into 3D
Shapes
[0066] Porcine skin was soaked in 0.2% calcium hydroxide solution for 5
days to loosen the epidermis and hair, and the epidermis and hair were
mechanically removed by scraping. De-epidermized, de-haired dermis was
neutralized with acetic acid and washed extensively in distilled water for 48
hours.
Cleaned dermis was then de-cellularized by soaking in a solution containing 2%
(w/v) sodium deoxycholate solution and 10 mM ETDA for 40 hours. After
decellularization, the dermal matrix (-2 mm thick) was washed in PBS solution
to
remove residual detergent.
[0067] To shape the dermal sheet into a 3D curved tissue matrix, the
sheet was partially dehydrated by blot drying with GAMMA WIPES . The sheet
was then mounted onto a mold having a semi-spherical shape under tension (-5
N). The sheet was secured in place with sutures. The mounted material was
packaged in a foil-to-foil bag and irradiated with 16.7 kGy e-beam radiation.
E-
beam treated dermis was removed from the mold and fully rehydrated in PBS
solution. An untreated sheet of acellular porcine dermis 90 and shaped tissue
products 92 are shown in Fig. 10. As shown, the shaped tissue product
maintained a stable three-dimensional cup shape, but remained flexible and had
a
feel that was very similar to the untreated acellular sheet.
Experiment #4- Shaping of Human Dermal Sheets into 3D Forms
[0068] Human skin was obtained from a cadaver donor. The epidermis
was removed using a dernnatome. The dermal tissue (-2.5 mm) was de-
cellularized with 2% (w/v) sodium deoxycholate for 24 hours and was washed in
PBS for 20 hours to remove detergent residues. A piece of decellularized
dermal
21
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
sheet was blot-dried and mounted onto a plastic cone (9 = 4 cm). A second
plastic cone was placed on top to secure the dermal matrix in the cone
configuration. The construct was packaged in a foil-to-foil bag and irradiated
by e-
beam at a dose of 16.7 kGy.
[0069] E-beam treated dermis retained its cone shape after it was
removed from the plastic molds (not shown). Other shapes were produced by
folding dermal sheets to produce angled/folder configurations (results not
shown).
Experiment #5¨ Reorientation of Collagen Fibers in Acellular Porcine Artery
[0070] Porcine carotid arteries (7 to 8 cm long) were dissected from
animals' necks and were separated into two groups according to their outer
diameter (Group A, 5 to 6 mm; Group B, 7 to 8 mm). Dissected arteries were
rinsed for 30 min with 0.5% (w/v) TRITON X100 to remove blood. Arteries were
frozen and thawed 3 times in 2% sodium deoxycholate solution containing an
antibiotic cocktail (50 pg/ml penicillin, 1.25 pg/ml amphotercin B, and 50
pg/ml
streptomycin). After the freeze-thaw cycles, arteries were de-cellularized at
37 C
for 96 hours in the same sodium deoxycholate solution. De-cellularized
arteries
were washed 4 times (2 hours for each wash) with Dulbecco's PBS with 50 u/ml
penicillin, 1.25 ug/ml amphotercin B, and 50 ug/ml streptomycin. Half of the
processed arteries from Group A and Group B were stored at 4 C in PBS with the
antibiotics. The other half of the processed arteries were subjected to gamma
irradiation. A 5-mm surgical drain was inserted into each artery for support,
and
then the artery was blot-dried with GAMMA WIPES . The blotting process was
also used to applied mechanical pressure (compression) to the tissue matrix to
cause reorientation of collagen fibers within the tissue matrix.
22
CA 02804592 2013-01-07
WO 2012/006390
PCT/1JS2011/043129
[0071] After blot-drying, arteries were packaged in sterile plastic film
bags and secondary foil-to-foil bags. The arteries were irradiated with 1 kGy
gamma radiation. The de-cellularization process removed endothelial cells from
the intima, smooth muscle cells from the media, and fibroblast cells in the
adventitia. The de-cellularized arteries comprised very loose collagen and
elastin
tissue matrices that could collapse on their own weight, while the shaped
product
(dehydrated and collagen realigned) maintained an open lumen with a tubular
structure when laid on a flat surface.
[0072] Figs. 11A-11D are scanning electron micrographs for an acellular
porcine artery (Figs. 11A and 11B) that had not be blot dried and irradiated,
and
for a shaped tissue product (Figs. 11C and 11D) comprising an acellular artery
that had been blot dried and irradiate. The partial dehydration and
irradiation
increased the strength of the arterial matrix, preventing the tubular
structure from
collapsing under its own weight. In addition, as can be seen in Figs. 11A-11D,
the
treated arterial tissue matrices had more dense collagen fibers that were
reoriented during blot drying.
Experiment #6¨ Stabilization of Rolled Human and Porcine Dermis Matrices
[0073] ALLODERM and STRATTICETm dermal tissue matrices were
obtained from LifeCell Corporation. ALLODERM is a freeze-dried acellular
human dermal matrix, and STRATTICETm is a hydrated acellular porcine dermal
matrix. The ALLODERM tissue matrices were aseptically rehydrated in PBS
and washed three times to remove cryo-protectants. The rehydrated human
dermal matrices were stored at 4 C until ready to use. STRATTICETm tissue
matrices was asceptically washed in PBS three times to remove tissue
preservation solutions.
23
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
[0074] After hydration, the human and porcine dermal tissue matrices
were flexible sheets that could be rolled into a cylindrical shape. However,
the
rolled sheets would easily unfolded to flat sheets when placed into a saline
solution. To stabilize the sheets rolls, human and porcine dermal sheets were
blot-dried to a water content of about 75%(w/w) for ALLODERMO and 70%(w/w)
for STRATTICETm. The blot-dried (partially dehydrated) sheets were rolled
using
surgical drain tubes. The rolled sheets were packaged in sterile plastic film
bags
and secondary foil-to-foil bags and were irradiated with 1 kGy gamma. After
gamma irradiation, the rolled dermal matrices did not unfold when placed in
saline
solutions.
[0075] The samples were prepared for SEM analysis, as described in
example 1. Figs. 12A and 12B are SEM images of shaped human dermal
acellular tissue matrices and shaped porcine dermal acellular tissue matrices,
respectively. As shown, the collagen fibers had areas of compression 110 and
stretching 120 where the fibers were stably reoriented to form a tubular
structure.
Acellular Tissue Matrices
[0076] The term "acellular tissue matrix," as used herein, refers
generally to any tissue matrix that is substantially free of cells and/or
cellular
components. Skin, parts of skin (e.g., dermis), and other tissues such as
blood
vessels, heart valves, fascia, cartilage, bone, and nerve connective tissue
may be
used to create acellular matrices within the scope of the present disclosure.
Acellular tissue matrices can be tested or evaluated to determine if they are
substantially free of cell and/or cellular components in a number of ways. For
example, processed tissues can be inspected with light microscopy to determine
if
24
CA 02804592 2013-01-07
WO 2012/006390
PCT/1JS2011/043129
cells (live or dead) and/or cellular components remain. In addition, certain
assays
can be used to identify the presence of cells or cellular components. For
example, DNA or other nucleic acid assays can be used to quantify remaining
nuclear materials within the tissue matrices. Generally, the absence of
remaining
DNA or other nucleic acids will be indicative of complete decellularization
(i.e.,
removal of cells and/or cellular components). Finally, other assays that
identify
cell-specific components (e.g., surface antigens) can be used to determine if
the
tissue matrices are acellular.
[0077] In general, the steps involved in the production of an acellular
tissue matrix include harvesting the tissue from a donor (e.g., a human
cadaver or
animal source) and cell removal under conditions that preserve biological and
structural function. In certain embodiments, the process includes chemical
treatment to stabilize the tissue and avoid biochemical and structural
degradation
together with or before cell removal. In various embodiments, the stabilizing
solution arrests and prevents osmotic, hypoxic, autolytic, and proteolytic
degradation, protects against microbial contamination, and reduces mechanical
damage that can occur with tissues that contain, for example, smooth muscle
components (e.g., blood vessels). The stabilizing solution may contain an
appropriate buffer, one or more antioxidants, one or more oncotic agents, one
or
more antibiotics, one or more protease inhibitors, and/or one or more smooth
muscle relaxants.
[0078] The tissue is then placed in a decellularization solution to
remove
viable cells (e.g., epithelial cells, endothelial cells, smooth muscle cells,
and
fibroblasts) from the structural matrix without damaging the biological and
structural integrity of the collagen matrix. The decellularization solution
may
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
contain an appropriate buffer, salt, an antibiotic, one or more detergents
(e.g.,
TRITON X100TM, sodium deoxycholate, polyoxyethylene (20) sorbitan mono-
oleate), one or more agents to prevent cross-linking, one or more protease
inhibitors, and/or one or more enzymes. In some embodiments, the
decellularization solution comprises 1% TRITON X100TM in RPM! media with
Gentamicin and 25 mM EDTA (ethylenediaminetetraacetic acid). In some
embodiments, the tissue is incubated in the decellularization solution
overnight at
37 C with gentle shaking at 90 rpm. In certain embodiments, additional
detergents may be used to remove fat from the tissue sample. For example, in
some embodiments, 2% sodium deoxycholate is added to the decellularization
solution.
[0079] After the decellularization process, the tissue sample is washed
thoroughly with saline. In some exemplary embodiments, e.g., when xenogenic
material is used, the decellularized tissue is then treated overnight at room
temperature with a deoxyribonuclease (DNase) solution. In some embodiments,
the tissue sample is treated with a DNase solution prepared in DNase buffer
(20
mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 20 mM CaCl2
and 20 mM MgC12). Optionally, an antibiotic solution (e.g., Gentamicin) may be
added to the DNase solution. Any suitable buffer can be used as long as the
buffer provides suitable DNase activity.
[0080] While an acellular tissue matrix may be made from one or more
individuals of the same species as the recipient of the acellular tissue
matrix graft,
this is not necessarily the case. Thus, for example, an acellular tissue
matrix may
be made from porcine tissue and implanted in a human patient. Species that can
serve as recipients of acellular tissue matrix and donors of tissues or organs
for
26
CA 02804592 2013-01-07
WO 2012/006390
PCT/US2011/043129
the production of the acellular tissue matrix include, without limitation,
mammals,
such as humans, nonhuman primates (e.g., monkeys, baboons, or chimpanzees),
pigs, cows, horses, goats, sheep, dogs, cats, rabbits, guinea pigs, gerbils,
hamsters, rats, or mice.
[0081] Elimination of the a-gal epitopes from the collagen-containing
material may diminish the immune response against the collagen-containing
material. The a-gal epitope is expressed in non-primate mammals and in New
World monkeys (monkeys of South America) as well as on macromolecules such
as proteoglycans of the extracellular components. U. Galili et al., J. Biol.
Chem.
263: 17755 (1988). This epitope is absent in Old World primates (monkeys of
Asia and Africa and apes) and humans, however. Id. Anti-gal antibodies are
produced in humans and primates as a result of an immune response to a-gal
epitope carbohydrate structures on gastrointestinal bacteria. U. Galili et
al., Infect.
lmmun. 56: 1730 (1988); R. M. Hamadeh et al., J. Clin. Invest. 89: 1223
(1992).
[0082] Since non-primate mammals (e.g., pigs) produce a-gal epitopes,
xenotransplantation of collagen-containing material from these mammals into
primates often results in rejection because of primate anti-Gal binding to
these
epitopes on the collagen-containing material. The binding results in the
destruction of the collagen-containing material by complement fixation and by
antibody dependent cell cytotoxicity. U. Galili et al., Immunology Today 14:
480
(1993); M. Sandrin et al., Proc. Natl. Acad. Sci. USA 90: 11391 (1993); H.
Good et
al., Transplant. Proc. 24: 559 (1992); B. H. Collins et al., J. Immunol. 154:
5500
(1995). Furthermore, xenotransplantation results in major activation of the
immune system to produce increased amounts of high affinity anti-gal
antibodies.
Accordingly, in some embodiments, when animals that produce a-gal epitopes are
27
used as the tissue source, the substantial elimination of a-gal epitopes from
cells
and from extracellular components of the collagen-containing material, and the
prevention of re-expression of cellular a-gal epitopes can diminish the immune
response against the collagen-containing material associated with anti-gal
antibody binding to a-gal epitopes.
[0083] To remove a-gal epitopes, after washing the tissue
thoroughly
with saline to remove the DNase solution, the tissue sample may be subjected
to
one or more enzymatic treatments to remove certain immunogenic antigens, if
present in the sample. In some embodiments, the tissue sample may be treated
with an a-galactosidase enzyme to eliminate a-gal epitopes if present in the
tissue. In some embodiments, the tissue sample is treated with a-galactosidase
at a concentration of 300 U/L prepared in 100 mM phosphate buffer at pH 6Ø
In
other embodiments, the concentration of a-galactosidase is increased to 400
U/L
for adequate removal of the a-gal epitopes from the harvested tissue. Any
suitable enzyme concentration and buffer can be used as long as sufficient
removal of antigens is achieved.
[0084] Alternatively, rather than treating the tissue with enzymes,
animals that have been genetically modified to lack one or more antigenic
epitopes may be selected as the tissue source. For example, animals (e.g.,
pigs)
that have been genetically engineered to lack the terminal a-galactose moiety
can
be selected as the tissue source. For descriptions of appropriate animals see
co-
pending U.S. Application Serial No. 10/896,594 and U.S. Patent No. 6,166,288.
In
addition, certain exemplary methods of processing tissues to produce acellular
matrices with or without reduced amounts of or lacking alpha-1,3-galactose
28
CA 2804592 2018-04-05
moieties, are described in Xu, Hui. et at., "A Porcine-Derived Acellular
Dermal
Scaffold that Supports Soft Tissue Regeneration: Removal of Terminal Galactose-
a-(1,3)-Galactose and Retention of Matrix Structure," Tissue Engineering, Vol.
15,
1-13 (2009).
[0085] After the acellular tissue matrix is formed,
histocompatible, viable
cells may optionally be seeded in the acellular tissue matrix to produce a
graft that
may be further remodeled by the host. In some embodiments, histocompatible
viable cells may be added to the matrices by standard in vitro cell co-
culturing
techniques prior to transplantation, or by in vivo repopulation following
transplantation. In vivo repopulation can be by the recipient's own cells
migrating
into the acellular tissue matrix or by infusing or injecting cells obtained
from the
recipient or histocompatible cells from another donor into the acellular
tissue
matrix in situ. Various cell types can be used, including embryonic stem
cells,
adult stem cells (e.g. mesenchymal stem cells), and/or neuronal cells. In
various
embodiments, the cells can be directly applied to the inner portion of the
acellular
tissue matrix just before or after implantation. In certain embodiments, the
cells
can be placed within the acellular tissue matrix to be implanted, and cultured
prior
to implantation.
29
CA 2804592 2018-04-05
